You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1820 Results
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
May 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
May 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
May 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
May 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • leuprolide - long-acting formulation
Jun 2017
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment metastatic castration sensitive prostate cancer (mCSPC), with specific clinical criteria
Apr 2022
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria
Exceptional Access Program
    apalutamide - For the treatment of metastatic castration sensitive prostate cancer (mCSPC), according to clinical criteria
Mar 2024
Regimen
Cancer Type:
Gynecologic, 
Vulva
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Penile
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Apr 2023
Regimen
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Apr 2023

Pages